Elyvia Biomedics GmbH

Elyvia is developing a next-generation diagnostic test for the early detection of ovarian cancer using only a drop of blood — no venipuncture, no central lab. The platform combines a self-calibrating biosensor with an AI-driven risk algorithm to deliver lab-grade accuracy in clinics, gynecology offices, or even at home. By integrating multiple biomarkers with patient data such as age, Elyvia’s test significantly outperforms current CA125-based methods in both sensitivity and specificity. Built on the company’s proprietary molecular counter technology, the device is compatible with smartphones and standard optical readers, enabling scalable, cost-effective, and accessible cancer diagnostics at population level.